Is fetuin-A a biomarker of dialysis access dysfunction?

Area of Science:

• Nephrology and Vascular Surgery
• Biomarker Discovery
• Dialysis Access Management

Background:

• Arteriovenous (AV) access function in hemodialysis (HD) patients is compromised by artery stiffness and venous stenosis, often linked to vascular calcification and inflammation.
• Fetuin-A, a potent inhibitor of vascular calcification and an anti-inflammatory agent, may play a crucial role in maintaining AV access health.

Purpose of the Study:

• To investigate the relationship between baseline serum fetuin-A levels and arteriovenous (AV) access blood flow (Q_A) in hemodialysis (HD) patients.
• To assess the association of fetuin-A levels with AV access failure (thrombosis or stenosis intervention) and primary unassisted patency during follow-up.

Main Methods:

• Prospective study measuring baseline serum fetuin-A levels and AV access Q_A in 64 HD patients undergoing routine surveillance.
• Patients categorized into tertiles based on baseline fetuin-A levels (<0.5 g/L, 0.5-1.20 g/L, >1.20 g/L).
• Analysis included correlation, comparison between groups, Cox regression, and Kaplan-Meier survival analysis.

Main Results:

• Serum fetuin-A positively correlated with AV access Q_A (Spearman coefficient = 0.311, p=0.012).
• Patients experiencing AV access failure had significantly lower baseline fetuin-A and Q_A compared to those without failure (p=0.027 and p<0.001, respectively).
• The highest AV access failure rate (34.8%) occurred in the lowest fetuin-A tertile. Patients with the highest fetuin-A levels demonstrated the best primary unassisted AV access patency (log-rank test, p=0.030).

Conclusions:

• Baseline serum fetuin-A levels are associated with AV access function and patency in hemodialysis patients.
• Lower fetuin-A levels may indicate a higher risk of AV access dysfunction and failure.
• Fetuin-A holds potential as a biomarker for identifying HD patients needing closer dialysis access surveillance.